Markets /MDNAF Medicenna Therapeutics Corp. MDNAF Full chart Compare Add to watchlist Set alert Price alert · MDNAF Alert when the price is Price abovePrice below Price level Set alert All alert types 0.16 USD -0.10 (-37.25%) Regular-session close 0.1596 Day range 0.2127 0.1596 52-week range 1.30 YTD -76.33%1 year -84.47% Overview Chart ChartPrice historyFinancials FinancialsValuation & healthEarnings EarningsDividends & splitsAnalysts News Ownership Options More ComparisonSignalsTrend ScoreDiscussionNotesPositionsAlerts News All sources Benzinga only 22 hours ago globenewswire.com Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update MDNA11 Phase 1/2 ABILITY-1 completes 152-patient enrollment and demonstrates 40% objective response rate (ORR) and 80% disease control rate (DCR) in biomarker-enriched gastrointestinal cancers